Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer

Zhou Zhou; Derek H. Tang; Jipan Xie; Rajeev Ayyagari; Eric Wu; Polly A. Niravath

doi:10.1007/s12325-017-0644-2

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer

Zhou Zhou, Derek H. Tang, Jipan Xie, Rajeev Ayyagari, Eric Wu, Polly A. Niravath

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Introduction: A major treatment goal for advanced breast cancer (ABC) is to maintain or ideally improve patient quality of life (QoL). Given the changing disease landscape, this systematic literature review (SLR) aims to assess the impact of endocrine therapies (ET), including ET monotherapy (ET mono) and ET combined with targeted therapy (ET + TT), on QoL of women with HR+/HER2− ABC. Methods: A SLR was conducted to identify randomized controlled trials (RCTs) meeting the following criteria: (1) included ET mono or ET + TT, (2) reported QoL outcomes, (3) focused on women with HR+/HER2− ABC, and (4) published after 2007 (when standardized HER2 testing became available). The databases searched included MEDLINE, EMBASE, Cochrane Library, and key conference proceedings from 2013 to 2016. QoL outcomes for ET mono, ET + TT, and comparisons between the two were summarized from the identified trials. Results: A total of 11 studies (representing 6 RCTs) were identified. The study populations included first-line (5 studies) and ET-failure settings (6 studies). Across settings, global health status (GHS) maintained or deteriorated slightly on these treatments during the trial period. Time to deterioration (TTD) in QoL measured by GHS was analyzed in 6 studies and 4 RCTs. In the first-line setting, reported median TTD in GHS was similar between ET mono and ET + TT (7.2–13.8 months in ET mono; 11.1 months in ET + TT). In the ET-failure setting, ET + TT showed significantly longer TTD vs. ET mono in GHS (median 5.6–8.4 months in ET mono and 8.3–11.7 months in ET + TT) and some additional domains. Conclusions: ET + TT users experienced similar QoL in the first-line and ET-failure setting relative to patients on ET mono. Moreover, ET + TT users experienced better QoL outcomes in some domains in the ET-failure setting relative to ET mono users. Funding: Novartis.

Original language	English (US)
Pages (from-to)	2566-2584
Number of pages	19
Journal	Advances in Therapy
Volume	34
Issue number	12
DOIs	https://doi.org/10.1007/s12325-017-0644-2
State	Published - Dec 1 2017

Keywords

Advanced breast cancer
Endocrine therapy
HR+/HER2−
Quality of life
Systematic literature review
Targeted therapy

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s12325-017-0644-2

Cite this

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer. / Zhou, Zhou; Tang, Derek H.; Xie, Jipan et al.
In: Advances in Therapy, Vol. 34, No. 12, 01.12.2017, p. 2566-2584.

Research output: Contribution to journal › Review article › peer-review

@article{8966a1d2c47c4c688acd45b6e3f0ab47,

title = "Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer",

abstract = "Introduction: A major treatment goal for advanced breast cancer (ABC) is to maintain or ideally improve patient quality of life (QoL). Given the changing disease landscape, this systematic literature review (SLR) aims to assess the impact of endocrine therapies (ET), including ET monotherapy (ET mono) and ET combined with targeted therapy (ET + TT), on QoL of women with HR+/HER2− ABC. Methods: A SLR was conducted to identify randomized controlled trials (RCTs) meeting the following criteria: (1) included ET mono or ET + TT, (2) reported QoL outcomes, (3) focused on women with HR+/HER2− ABC, and (4) published after 2007 (when standardized HER2 testing became available). The databases searched included MEDLINE, EMBASE, Cochrane Library, and key conference proceedings from 2013 to 2016. QoL outcomes for ET mono, ET + TT, and comparisons between the two were summarized from the identified trials. Results: A total of 11 studies (representing 6 RCTs) were identified. The study populations included first-line (5 studies) and ET-failure settings (6 studies). Across settings, global health status (GHS) maintained or deteriorated slightly on these treatments during the trial period. Time to deterioration (TTD) in QoL measured by GHS was analyzed in 6 studies and 4 RCTs. In the first-line setting, reported median TTD in GHS was similar between ET mono and ET + TT (7.2–13.8 months in ET mono; 11.1 months in ET + TT). In the ET-failure setting, ET + TT showed significantly longer TTD vs. ET mono in GHS (median 5.6–8.4 months in ET mono and 8.3–11.7 months in ET + TT) and some additional domains. Conclusions: ET + TT users experienced similar QoL in the first-line and ET-failure setting relative to patients on ET mono. Moreover, ET + TT users experienced better QoL outcomes in some domains in the ET-failure setting relative to ET mono users. Funding: Novartis.",

keywords = "Advanced breast cancer, Endocrine therapy, HR+/HER2−, Quality of life, Systematic literature review, Targeted therapy",

author = "Zhou Zhou and Tang, {Derek H.} and Jipan Xie and Rajeev Ayyagari and Eric Wu and Niravath, {Polly A.}",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s12325-017-0644-2",

language = "English (US)",

volume = "34",

pages = "2566--2584",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Health Communications Inc.",

number = "12",

}

TY - JOUR

T1 - Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer

AU - Zhou, Zhou

AU - Tang, Derek H.

AU - Xie, Jipan

AU - Ayyagari, Rajeev

AU - Wu, Eric

AU - Niravath, Polly A.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Introduction: A major treatment goal for advanced breast cancer (ABC) is to maintain or ideally improve patient quality of life (QoL). Given the changing disease landscape, this systematic literature review (SLR) aims to assess the impact of endocrine therapies (ET), including ET monotherapy (ET mono) and ET combined with targeted therapy (ET + TT), on QoL of women with HR+/HER2− ABC. Methods: A SLR was conducted to identify randomized controlled trials (RCTs) meeting the following criteria: (1) included ET mono or ET + TT, (2) reported QoL outcomes, (3) focused on women with HR+/HER2− ABC, and (4) published after 2007 (when standardized HER2 testing became available). The databases searched included MEDLINE, EMBASE, Cochrane Library, and key conference proceedings from 2013 to 2016. QoL outcomes for ET mono, ET + TT, and comparisons between the two were summarized from the identified trials. Results: A total of 11 studies (representing 6 RCTs) were identified. The study populations included first-line (5 studies) and ET-failure settings (6 studies). Across settings, global health status (GHS) maintained or deteriorated slightly on these treatments during the trial period. Time to deterioration (TTD) in QoL measured by GHS was analyzed in 6 studies and 4 RCTs. In the first-line setting, reported median TTD in GHS was similar between ET mono and ET + TT (7.2–13.8 months in ET mono; 11.1 months in ET + TT). In the ET-failure setting, ET + TT showed significantly longer TTD vs. ET mono in GHS (median 5.6–8.4 months in ET mono and 8.3–11.7 months in ET + TT) and some additional domains. Conclusions: ET + TT users experienced similar QoL in the first-line and ET-failure setting relative to patients on ET mono. Moreover, ET + TT users experienced better QoL outcomes in some domains in the ET-failure setting relative to ET mono users. Funding: Novartis.

AB - Introduction: A major treatment goal for advanced breast cancer (ABC) is to maintain or ideally improve patient quality of life (QoL). Given the changing disease landscape, this systematic literature review (SLR) aims to assess the impact of endocrine therapies (ET), including ET monotherapy (ET mono) and ET combined with targeted therapy (ET + TT), on QoL of women with HR+/HER2− ABC. Methods: A SLR was conducted to identify randomized controlled trials (RCTs) meeting the following criteria: (1) included ET mono or ET + TT, (2) reported QoL outcomes, (3) focused on women with HR+/HER2− ABC, and (4) published after 2007 (when standardized HER2 testing became available). The databases searched included MEDLINE, EMBASE, Cochrane Library, and key conference proceedings from 2013 to 2016. QoL outcomes for ET mono, ET + TT, and comparisons between the two were summarized from the identified trials. Results: A total of 11 studies (representing 6 RCTs) were identified. The study populations included first-line (5 studies) and ET-failure settings (6 studies). Across settings, global health status (GHS) maintained or deteriorated slightly on these treatments during the trial period. Time to deterioration (TTD) in QoL measured by GHS was analyzed in 6 studies and 4 RCTs. In the first-line setting, reported median TTD in GHS was similar between ET mono and ET + TT (7.2–13.8 months in ET mono; 11.1 months in ET + TT). In the ET-failure setting, ET + TT showed significantly longer TTD vs. ET mono in GHS (median 5.6–8.4 months in ET mono and 8.3–11.7 months in ET + TT) and some additional domains. Conclusions: ET + TT users experienced similar QoL in the first-line and ET-failure setting relative to patients on ET mono. Moreover, ET + TT users experienced better QoL outcomes in some domains in the ET-failure setting relative to ET mono users. Funding: Novartis.

KW - Advanced breast cancer

KW - Endocrine therapy

KW - HR+/HER2−

KW - Quality of life

KW - Systematic literature review

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85034270247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034270247&partnerID=8YFLogxK

U2 - 10.1007/s12325-017-0644-2

DO - 10.1007/s12325-017-0644-2

M3 - Review article

C2 - 29143928

AN - SCOPUS:85034270247

SN - 0741-238X

VL - 34

SP - 2566

EP - 2584

JO - Advances in Therapy

JF - Advances in Therapy

IS - 12

ER -

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this